US authorities probing Emergent BioSolutions over COVID-19 vaccine issues - filing
Reuters
Published Jul 30, 2021 10:18AM ET
Updated Jul 30, 2021 12:06PM ET
WASHINGTON (Reuters) -Drug manufacturer Emergent BioSolutions Inc said on Friday it has received inquiries and subpoenas from a swathe of U.S. authorities related to its abilities to manufacture COVID-19 bulk drug substance.
Emergent came under regulatory scrutiny after an error led to millions of vaccine doses being ruined at its manufacturing facility in Baltimore, which was producing bulk drug substance for Johnson & Johnson (NYSE:JNJ)'s COVID-19 vaccine.
The U.S. Food and Drug Administration (FDA) in April halted operations at the plant after it discovered that ingredients from AstraZeneca (NASDAQ:AZN)'s COVID-19 vaccine, also being produced there at that time, contaminated a batch of J&J's vaccines.
Emergent in a filing https://investors.emergentbiosolutions.com/node/20661/html on Friday said it has received "preliminary inquiries and subpoenas to produce documents" from the lawmakers, the Department of Justice, the Securities and Exchange Commission, the Financial Industry Regulatory Authority, and Maryland and New York Attorneys General.
The Department of Justice declined to comment on the matter.
Emergent said it was producing and has produced documents as required in response and will continue to cooperate with the government inquiries.
An FDA inspection in April turned up a long list of sanitary problems and bad manufacturing practices at the facility, including failure to train personnel to avoid cross contamination of COVID-19 vaccines from J&J and AstraZeneca.
Emergent said on Wednesday production at the Baltimore facility will now resume, following remedial actions, additional reviews and collaboration with the FDA and its manufacturing partners.
An FDA spokesperson said on Thursday the facility has not yet received any authorization for a COVID-19 vaccine, but may produce vaccine substance in advance of future inspections by the health regulator.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.